Cellular Biomedicine Group to Report Fourth Quarter and Full Year 2019 Results on February 28, 2020

NEW YORK and SHANGHAI, Feb. 26, 2020 /PRNewswire/ -- Cellular Biomedicine Group, Inc. (NASDAQ: CBMG) (“CBMG” or the “Company”), a biopharmaceutical firm engaged in the drug development of immunotherapies for cancer and stem cell therapies for degenerative diseases, today announced that it will release its financial results for the fourth quarter and full year ended December 31, 2019 after the market closes on Friday, February 28, 2020.

The Company will host a conference call and webcast with the investment community on Friday, February 28^th at 4:30 p.m. Eastern Time, featuring remarks by Tony Liu, Executive Director, CEO and CFO of CBMG.

About Cellular Biomedicine Group, Inc.
Cellular Biomedicine Group, Inc. is a biopharmaceutical firm engaged in the drug development of immunotherapies for cancer and stem cell therapies for degenerative diseases. For more information, please visit https://www.cellbiomedgroup.com/.

For more information, please contact:

Company Contact:
Derrick C. Li
Head of Strategy and Investor Relations, CBMG
Phone: 917-717-0994
Email: derrick.li@cellbiomedgroup.com

Investor Contact:
Valter Pinto / Allison Soss
KCSA Strategic Communications
Phone: 212-896-1254 / 212-896-1267
Email: cellbiomed@kcsa.com

View original content to download multimedia:http://www.prnewswire.com/news-releases/cellular-biomedicine-group-to-report-fourth-quarter-and-full-year-2019-results-on-february-28-2020-301011725.html

SOURCE Cellular Biomedicine Group, Inc.